On July 25, 2024 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, reported an update on recent business development activity, including three recently closed transactions that are expected to enhance the company’s antibody-drug conjugate (ADC) capabilities (Press release, Immunome, JUL 25, 2024, View Source [SID1234645098]). Immunome acquired worldwide, exclusive rights to:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A panel of antibodies against an undisclosed solid tumor target from Nectin Therapeutics
A panel of antibodies against an undisclosed solid tumor target from Bluefin Biomedicine
Four antibodies against undisclosed targets from OncoResponse
In addition, the company previously announced the purchase of 28 antibodies from Atreca in May 2024 and the exclusive license of IM-1021 along with the underlying ADC platform technology from Zentalis in January 2024. None of the acquired antibodies are known to share the same target as an FDA approved ADC.
"Immunome’s long-term vision remains centered on a broad pipeline of targeted therapies, particularly ADCs against novel targets," said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "Focused business development activity complements our highly productive internal discovery efforts and has led to an advancing pipeline of product candidates."
"Successful ADC development requires addressing the unique biology of each target with appropriate antibodies, linkers and payloads," added Jack Higgins, PhD, Chief Scientific Officer of Immunome. "Our research team has identified multiple promising ADC targets. We have also established a toolbox that includes multiple linkers, our differentiated proprietary TOP1 inhibitor and numerous antibodies. We believe that the next generation of ADCs will bring tremendous benefit to cancer patients."